As per the agreement, CCS’s highly flexible service becomes available for EMD Millipore’s well-proven assay cell lines, improving customers’ drug discovery and throughput functional screening capabilities.
EMD Millipore Lead Discovery director Umesh Patel said customers depending on its GPCR and Ion Channel cell line products will be provided with a complete solution to support their drug discovery needs.
CCS managing director and president Oliver Wehmeier said the agreement allows them to offer their services for EMD Millipore’s cell lines, enabling the customers to conviniently obtain high quality cell based reagents for their screening approaches.
EMD Millipore operates more than 180 GPC Rexpressing cell lines and 60 ion channel-expressing cell lines, from which CCS can produce custom assay-ready frozen cells or membranes and may even use the cells as a host for transient bulk transfections.